medigraphic.com
ISSN 1561-2988 (Print)

2012, Number 3

<< Back Next >>

Rev Cubana Farm 2012; 46 (3)

Comparative effects of D-004, Imipramine and Sertraline in the forced swimming test in mice

Carbajal QD, Molina CV, Ravelo CY, Mas FR

Language: Spanish
References: 29
Page: 343-351
PDF size: 51.98 Kb.


ABSTRACT

Introduction: finasteride is a 5 a-reductase inhibitor to treat benign prostatic hyperplasia (BPH) and one of the adverse effects is the increase of depressive symptoms. D-004 is a lipid extract from the real palm fruit (Roystonea regia) that is effective to prevent prostatic hyperplasia by inhibiting 5 a-reductase and shows moderate antidepressant effects in the forced swimming test (FST) and tail suspension test.
Objective: to compare the effects of D-004, Imipramine and Sertraline on the duration of behaviours under conditions of immobility, swimming and climbing in the forced swimming test.
Methods: mice were randomly distributed in 8 groups: control (vehicle), 3 treated with D-004 (100, 250 and 500 mg/kg), 2 with Sertraline and 2 with Imipramine (30 and 50 mg/kg) respectively. Mice were placed in a glass cylinder containing 6 cm high column of water and their behaviours were quantified.
Results: oral administration of D-004 (100, 250 and 500 mg/kg) during 14 days reduced the length of time of immobility with respect to the control group (17, 22 and 25 %), and significantly increased the behaviours at swimming by 1.58, 1.68 and 1.74 times. This is a moderate effect (25 %) if compared with Sertraline and Imipramine (ł 60 %) The doses of 250 and 500 mg/kg showed that climbing behaviours were 2.79 and 3.55 times higher than the control group. The results were similar to those of Imipramine but less effective.
Conclusions: D-004 showed moderate antidepressant effect. This fact could help in the treatment of patients with benign prostatic hyperplasia, who reported similar depressive status.


REFERENCES

  1. Thorpe A, Neal D. Benign prostatic hyperplasia. Lancet. 2003;19:1359-67.

  2. Bhargava S, Canda AE, Chapple CR. A rational approach to benign prostatic hyperplasia evaluation: recent advances. Curr Opin Urol. 2004;14:1-6.

  3. Sandhu JS, Te AE. The role of 5 alpha-reductase inhibition as monotherapy in view of the MTOPS data. Curr Urol Rep. 2004;5:274-9.

  4. Djavan B, Fong YK, Chaudry A, Reissigl A, Anagnostou T, Bagher F, Walder M, Marihart S, Harik M and Marberger M. Progression delay in men with mild symptoms of bladder outlet obstruction: a comparative study of phytotherapy and watchful waiting. World J Urol. 2005;23:253-6.

  5. Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML. Adverse Side Effects of 5á-Reductase Inhibitors Therapy: Persistent Diminished Libido and Erectile Dysfunction and Depression in a Subset of Patients. J Sex Med. 2011;8(3):872-84.

  6. Römer B, Gass P. Finasteride-induced depression: new insights into possible pathomechanisms. J Cosmet Dermatol. 2010;9(4):331-2.

  7. Arruzazabala ML, Carbajal D, Mas R. Molina V, González V, Rodríguez E. Preventive effects of D-004, a lipid extract from Cuban royal palm (Rostoynea regia) fruits, on prostate hyperplasia induced with testosterone on intact and castrated rodents. Drugs Exptl Clin Res. 2004:227-34.

  8. Carbajal D, Arruzazabala ML, Más R, Molina V, Rodriguez E, Gonzalez V. Effect of D-004, a lipid extract from Cuban royal palm fruit, on inhibiting prostate hyperplasia induced with testosterone and dihydrotestosterone in rats. Curr Ther Res Clin & Exptl. 2004;65:505-14.

  9. Carbajal D, Molina V, Más R, Arruzazabala ML. Therapeutic effect of D-004, a lipid extract from Roystonea regia fruits, on prostate hyperplasia induced in rats. Drugs Exp Clin Res. 2005;31(5-6):193-7.

  10. Pérez Y, Menéndez R, Más R, González R. In vitro effect of D-004, a lipid extract from the Cuban Royal palm (Roystonea regia) fruits, on the activity of prostate steroid 5-alpha reductase. Curr Ther Res. 2006;67(6):396-405.

  11. Pérez Y, Menéndez R, Más R, González RM. In vitro effect of D-004, a lipid extract from the fruits of Cuban royal palm, on androgenic receptors of prostatic tissue. Rev CENIC Cien Biol. 2007;38(3):177-9.

  12. Arruzazabala ML, Más R, Carbajal D, Molina V. Effect of D-004, a lipid extract from Cuban royal palm fruit, on in vitro and in vivo effects mediated by a adrenoceptors in rat. Drugs R & D. 2005; 6:281-9.

  13. Gutiérrez A, Gámez R, Mas R, Noa M, Pardo B, Marrero G, et al. Oral subchronic toxicity of a lipid extract from Roystonea regia fruits in mice. Drugs Chem Toxicol. 2008;3:217-28.

  14. Fernández L, Más R, Fernández JC, Mendoza S, Gámez R, Pardo B. Effect of D-004, a lipid extract of the fruit of the Cuban Royal Palm (Roystonea regia) or the lipidosterolic extract of Saw Palmetto (Serenoa repens) on the sexual activity in male rats: a controlled experimental study. Curr Ther Res. 2008;69(1):65-74.

  15. Porsolt RD. Animal models of depression: utility for transgenic research. Rev Neurosci. 2000;11:53-5.

  16. Porsolt RD, Anton G, Deniel M, Jalfre M. Behavioral despair in rats: a new animal model sensitive to antidepressant treatments. Eur J Pharmacol. 1978;47:379-91.

  17. Carbajal D, Ravelo Y, Molina V, Más R, Arruzazabala ML. D-004, a lipid extract from royal palm fruit, exhibits antidepressant effects in the forced swim test and the tail suspension test in mice. Pharmacol Biochem & Behavior. 2009;92(2):465-8.

  18. Campos AR, Barros AI, Albuquerque FA, M Leal LK, Rao VS. Acute effects of guarana (Paullinia cupana Mart.) on mouse behaviour in forced swimming and open field tests. Phytother Res. 2005;19:441-3.

  19. Xu Y, Ku BS, Yao HY, Lin YH, Ma X, Zhang YH, Li XJ. The effects of Curcumin on depressive-like behaviors in mice. Eur J Pharmacol. 2005;518:40-6.

  20. Detke M, Rickels M, Lucki I. Active behaviors in the rat forced swimming test differentially activated by serotonergic and noradrenergic antidepressants. Psychopharmacology. 1995;121:66-72.

  21. Detke MJ, Johnson J, Lucki I. Acute and chronic antidepressant drug treatment in the rat forced swimming test model of depression. Exp Clin Psychopharmacol. 1997;5:107-12.

  22. Rénéric J-P, Lucki I. Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test. Psychopharmacology. 1998;136:190-7.

  23. Cryan J, Lucki I. Antidepressant-like behavioral effects mediated by 5-hydroxytryptamine2C receptors. J Pharmacol Exp Ther. 2000;295:1120-6.

  24. Willner P. The validity of animal models of depression. Psychopharmacology. 1984;83:1-16.

  25. Seyed Adel Moallem, Hossein Hosseinzadeh, Fatemeh Ghoncheh Evaluation of Antidepressant Effects of Aerial Parts of Echium vulgare on Mice. Iranian J Basic Medi Sci. 2007;10:189-96.

  26. Goodnick PJ and Goldstein BJ. Selective serotonin reuptake inhibitors in affective disorders. I. Basic pharmacology. J Psychopharmacol. 1998;12:S5-S20.

  27. Cottingham J. Thioridazine/Mellaril Parkinson's List Drug Database Index 2000:1-4. Available from: http://www.parkinsons-information-exchange-network-online.com/drugdb/126.html

  28. Reynolds JEF, Partitti K, Parson AV, Sweetman SC. The imipramine. In: Martindale. The extra Pharmacopeia. 31 ed. London: Pharmaceutical Press; 1996. p. 316-7.

  29. Wong DT, Perry KW, Bymaster FP. The discovery of fluoxetine hydrochloride (Prozac). Nature Rev Drug Discov. 2005;4:764-74.




2020     |     www.medigraphic.com